Skip to Content
Stock Analyst Update

Coronavirus Fear Threatens Royal Caribbean's Outlook

We plan to wait for more clarity on the persistence of the coronavirus before further altering our forward estimates.

Mentioned:

In narrow-moat Royal Caribbean’s (RCL) initial prognosis on Feb. 4 on the impact of the coronavirus, it disclosed that it had already canceled eight cruises from China through March 4, costing the company an estimated $0.25 per share. However, as the virus has escalated, Royal has canceled 10 more sailing trips from the region and altered itineraries. The incremental impact from the additional cancellations and changes will cost the business an estimated $0.40 per share, leading to a total impact of $0.65 per share thus far. However, similar to narrow-moat Carnival’s disclosure earlier this week, Royal offered that if it were to cancel all its trips in Asia until the end of April, it could cost the company another $0.55 in EPS. While company guidance for EPS of $10.40-$10.70 excluded any impact, we had already incorporated the $0.25 per share impact into our existing 2020 EPS forecast of $10.19. 

All in, the persistence of Covid-19 through April could cost Royal $1.20 per share, or about 11% of its estimated EPS. Furthermore, it would lead to the first year of flat EPS growth for Royal since 2012. More concerning, however, was the statement that recent bookings for its “broader business have also been softer,” suggesting the impact on Royal’s worldwide business has worsened since its earnings report just last week. We remind investors, as we did post-Carnival’s update, that in the years following the SARS (the next year was 2004), H1N1 (2010), and Zika (2017) outbreaks, Carnival and Royal both posted positive as-reported yield growth, conveying the resilience of demand across the industry. If we alter our model to incorporate the full effect of cancellations in Asia through April, our $134 fair value estimate fails to change materially, when we assume 2021 returns to the same yields and costs per diem as prior to the update. As a result, we plan to wait for more clarity on the persistence of the coronavirus before further altering our forward estimates. 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Jaime M. Katz does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.